Dr. Stanislaw R. Burzynski is an internationally-recognized physician and scientist who has pioneered the development and use of biologically-active peptides in diagnosing, preventing, and treating cancer and other diseases since 1967.
Dr. Burzynski graduated with honors from the Medical Academy in Lublin, Poland, and received his M.D. degree in 1967. Subsequently, in 1968 he earned his Ph.D. in biochemistry. He did his internship and residency from 1967 to 1970. From October 1970 to 1977 he was employed by Baylor College of Medicine in Houston, initially as a Research Associate and later as an Assistant Professor. While at Baylor. Dr. Burzynski's research was sponsored and partially funded by the National Cancer Institute. Doctors associated with M.D. Anderson Cancer Research Center also cooperated in this research. In 1977, Dr. Burzynski founded Burzynski Research Laboratories, and over a number of years the company expanded to Burzynski Research Institute, Inc., Burzynski Clinic, Pharmaceutical Plant, Aminocare Products, LP, Ampolgen Pharmaceuticals, and Lubgen Pharma. Dr. Burzynski serves as the President and Chairman of the Board of the Institute, and is the owner of the remaining companies.
Dr. Burzynski is the discoverer of antineoplastons, which are components of biochemical defense against cancer. He is also the discoverer of new treatments for cancer, viral infections including AIDS, autoimmune diseases, Parkinson's disease, neurofibromatosis, and restenosis; and is the author of the theories of biochemical defense against cancer and gene silencing in aging. Among his contributions are 238 patents covering 42 countries and over 300 scientific publications.